Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Electrolyte replacement becomes important if diarrhea is significant
Sulforaphane potentiates gemcitabine-mediated anti-cancer effects against intrahepatic cholangiocarcinoma by inhibiting HDAC activity
Another senior administration official said coverage of the drugs will expand to Medicare patients starting next year
Microdosing is not an FDA-approved regimen and has not been validated in clinical trials
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
US$ 25.11
US$ 28.70
US$ 29.03
